Adverse events—'serious' Duration of two years1 · COPD
Fluticasone/salmeterol (FPS) showed no clear difference in adverse events—'serious' Duration of two years1 compared with placebo (low certainty).
1 finding from 1 review
OR 1.08 [0.95, 1.23]
5531 participants
Low
Serious adverse events (proportion of patients) · patients with laparoscopic cholecystectomy.
It is very uncertain whether routine abdominal drain changes serious adverse events (proportion of patients) compared with 'no drain' (very low certainty).
1 finding from 1 review
Proportion of people with serious adverse events · acute exacerbations of chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of people with serious adverse events · acute exacerbations of chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of people with serious adverse events · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Adverse effect/event(s) ‐ serious adverse events · schizophrenia or related disorders
It is very uncertain whether modafinil changes adverse effect/event(s) ‐ serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events ‐ serious ocular events at 1 year · people with age‐related macular degeneration
The intervention showed no clear difference in adverse events ‐ serious ocular events at 1 year (moderate certainty).
1 finding from 1 review
Intervention not reported
Death and serious adverse events, including falls · participants after stroke
1 finding from 1 review
Intervention not reported
Death and serious adverse events, including falls · participants after stroke
1 finding from 1 review
Serious adverse events Duration 3 days to 3 weeks · acute asthma exacerbation
Antibiotics showed no clear difference in serious adverse events Duration 3 days to 3 weeks compared with placebo or usual care (low certainty).
1 finding from 1 review
Non‐serious adverse events assessed using ICH‐GCP · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic encephalopathy;…
It is very uncertain whether L‐ornithine L‐aspartate changes non‐serious adverse events assessed using ICH‐GCP compared with lactulose (very low certainty).
1 finding from 1 review
Non‐serious adverse events assessed using ICH‐GCP · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic encephalopathy;…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events assessed using ICH‐GCP · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic encephalopathy;…
It is very uncertain whether L‐ornithine L‐aspartate changes non‐serious adverse events assessed using ICH‐GCP compared with rifaximin (very low certainty).
1 finding from 1 review
Non‐serious adverse events assessed using ICH‐GCP
It is very uncertain whether L‐ornithine L aspartate changes non‐serious adverse events assessed using ICH‐GCP compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (dichotomous data) ‐ shock · critically ill patients
Corticosteroids showed no clear difference in serious adverse events (dichotomous data) ‐ shock compared with placebo compared (high certainty).
1 finding from 1 review
Incidence of serious adverse events ‐ not reported · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of serious adverse events ‐ not reported · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events/death: medium‐term outcomes · rehabilitation (medium‐term outcomes)
It is very uncertain whether summary of findings table ‐ More time changes serious adverse events/death: medium‐term outcomes compared with less time (very low certainty).
1 finding from 1 review
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
It is very uncertain whether brain‐derived neurotrophic factor changes participants with 1 or more serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
It is very uncertain whether cerebrospinal fluid filtration changes participants with 1 or more serious adverse events compared with plasma exchange (very low certainty).
1 finding from 1 review